Research programme: melanin-concentrating hormone receptor 1 antagonists - Kinexis
Alternative Names: KI 1361-17Latest Information Update: 16 Jul 2016
At a glance
- Originator Kinexis
- Class Small molecules
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders; Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 03 Apr 2007 The programme is available for licensing worldwide (http://www.kinexisinc.com)